Revvity Inc. (RVTY) - Total Assets
Based on the latest financial reports, Revvity Inc. (RVTY) holds total assets worth $12.00 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Revvity Inc. - Total Assets Trend (1985–2025)
This chart illustrates how Revvity Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Revvity Inc. (RVTY) total market value for the company's overall valuation and market capitalisation.
Revvity Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Revvity Inc.'s total assets of $12.00 Billion consist of 18.4% current assets and 81.6% non-current assets. Review total liabilities of Revvity Inc. to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.6% |
| Accounts Receivable | $744.67 Million | 6.1% |
| Inventory | $379.50 Million | 3.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.35 Billion | 19.3% |
| Goodwill | $6.61 Billion | 54.4% |
Asset Composition Trend (1985–2025)
This chart illustrates how Revvity Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Revvity Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revvity Inc.'s current assets represent 18.4% of total assets in 2025, a decrease from 62.5% in 1985.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2025, up from 4.1% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 73.0% of total assets, an increase from 6.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 54.4% of total assets.
Revvity Inc. Competitors by Total Assets
Key competitors of Revvity Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩335.22 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Revvity Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.72 | 3.58 | 2.01 |
| Quick Ratio | 1.41 | 2.99 | 1.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $889.67 Million | $1.67 Billion | $1.14 Billion |
Revvity Inc. - Advanced Valuation Insights
This section examines the relationship between Revvity Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.75 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | $12.17 Billion |
| Market Capitalization | $12.20 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Revvity Inc.'s assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Slight Asset Contraction: Revvity Inc.'s assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Revvity Inc. (1985–2025)
The table below shows the annual total assets of Revvity Inc. from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.17 Billion | -1.81% |
| 2024-12-31 | $12.39 Billion | -8.64% |
| 2023-12-31 | $13.56 Billion | -4.00% |
| 2022-12-31 | $14.13 Billion | -5.80% |
| 2021-12-31 | $15.00 Billion | +88.44% |
| 2020-12-31 | $7.96 Billion | +21.74% |
| 2019-12-31 | $6.54 Billion | +9.42% |
| 2018-12-31 | $5.98 Billion | -1.90% |
| 2017-12-31 | $6.09 Billion | +42.43% |
| 2016-12-31 | $4.28 Billion | +2.65% |
| 2015-12-31 | $4.17 Billion | +0.94% |
| 2014-12-31 | $4.13 Billion | +4.58% |
| 2013-12-31 | $3.95 Billion | +1.15% |
| 2012-12-31 | $3.90 Billion | +1.20% |
| 2011-12-31 | $3.86 Billion | +20.15% |
| 2010-12-31 | $3.21 Billion | +4.90% |
| 2009-12-31 | $3.06 Billion | +4.34% |
| 2008-12-31 | $2.93 Billion | -0.60% |
| 2007-12-31 | $2.95 Billion | +17.49% |
| 2006-12-31 | $2.51 Billion | -6.80% |
| 2005-12-31 | $2.69 Billion | +4.58% |
| 2004-12-31 | $2.58 Billion | -1.24% |
| 2003-12-31 | $2.61 Billion | -8.06% |
| 2002-12-31 | $2.84 Billion | -4.50% |
| 2001-12-31 | $2.97 Billion | +35.72% |
| 2000-12-31 | $2.19 Billion | +27.63% |
| 1999-12-31 | $1.71 Billion | +50.56% |
| 1998-12-31 | $1.14 Billion | +36.86% |
| 1997-12-31 | $832.10 Million | +1.12% |
| 1996-12-31 | $822.90 Million | +2.36% |
| 1995-12-31 | $803.90 Million | +1.36% |
| 1994-12-31 | $793.10 Million | +3.16% |
| 1993-12-31 | $768.80 Million | +2.55% |
| 1992-12-31 | $749.70 Million | +7.42% |
| 1991-12-31 | $697.90 Million | +3.36% |
| 1990-12-31 | $675.20 Million | +4.94% |
| 1989-12-31 | $643.40 Million | +19.30% |
| 1988-12-31 | $539.30 Million | +4.62% |
| 1987-12-31 | $515.50 Million | +15.79% |
| 1986-12-31 | $445.20 Million | +3.58% |
| 1985-12-31 | $429.80 Million | -- |
About Revvity Inc.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectio… Read more